...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Oncology Research >Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment.
【24h】

Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment.

机译：个性化肽疫苗和小剂量磷酸雌莫司汀联合治疗转移性激素难治性前列腺癌患者的疗效：预后因素分析。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aim of this study was to investigate prognostic factors of patients with metastatic hormone refractory prostate cancer (HRPC) under combined administration of personalized peptide vaccination and low-dose estramustine phosphate (EMP). From February 2001 to July 2004, 58 men with metastatic HRPC received the combination therapy of personalized peptide vaccination and low-dose EMP. Conducted immune monitorings for those patients were peptide-specific cytotoxic T lymphocyte (CTL) precursor analysis by interferon-gamma production and peptide-reactive immunoglobulin G (IgG) by an enzyme-linked immunosorbent assay. Clinical responses and survival times were also evaluated. The combination therapy was well tolerated with no major adverse effects. Increased levels of CTL precursors and IgG responses to the vaccinated peptides were observed in 29 of 37 (78%) patients and in 36 of 41 (88%) patients tested, respectively. A prostate-specific antigen decline of at least 50% occurred in 24% of patients. The median survival time was 17 months (95% confidence interval, 12-25 months). Cox proportional hazards analysis showed that a low number of lymphocytes (p = 0.0075, odds ratio 2.700), a negative immunological activity response after the vaccination (p = 0.0185, odds ratio 2.658), and poor performance status (p = 0.0347, odds ratio 2.569) were independent predictors of disease death. These encouraging results show the need for further evaluation of the combination of personalized peptide vaccination and low dose of EMP for metastatic HRPC patients.
机译：这项研究的目的是调查个性化肽疫苗和小剂量磷酸雌莫司汀（EMP）联合给药对转移性激素难治性前列腺癌（HRPC）患者的预后影响。从2001年2月至2004年7月，58例转移性HRPC男性接受了个性化肽疫苗接种和小剂量EMP的联合治疗。对这些患者进行的免疫监测是通过干扰素-γ产生的肽特异性细胞毒性T淋巴细胞（CTL）前体分析和通过酶联免疫吸附法进行的肽​​反应性免疫球蛋白G（IgG）。还评估了临床反应和生存时间。联合疗法耐受良好，无重大不良反应。在测试的37名患者中，有29名（78％）患者和41名（88％）患者中的36名分别观察到了CTL前体水平和对免疫肽的IgG应答增加。 24％的患者发生前列腺特异性抗原下降至少50％。中位生存时间为17个月（95％置信区间为12-25个月）。 Cox比例风险分析表明，淋巴细胞数量少（p = 0.0075，比值比为2.700），疫苗接种后免疫活性反应为阴性（p = 0.0185，比值比为2.658），且工作状态较差（p = 0.0347，比值比） 2.569）是疾病死亡的独立预测因子。这些令人鼓舞的结果表明，对于转移性HRPC患者，需要进一步评估个性化肽疫苗接种和低剂量EMP的组合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号